Welcome to Cypris Therapeutics

Chemistry is the core of our
Innovation

We leverage our proprietary synthetic chemistry and drug development expertise to create next generation therapies for unmet clinical needs.

About Us

From Atoms to Answers

We are a chemistry-focused pharmaceutical start-up company based in Syracuse, NY. Our technology was created from an industry-academia collaboration between Ichor Life Sciences & Florida State University.

As a formal partner of Ichor Life Sciences and Florida State University, we posses the full intellectual and material capabilities to translate our ideas into clinically viable therapies.

Our Mission

Building a better future

Our mission is to create solutions where they are urgently needed. Our cutting edge technology can be applied towards a variety of diseases. However, our immediate focus is addressing deadly diseases which have no effective treatments (Brain, Colon, & Pancreatic cancers). We believe that these patients are long overdue for quality, life-saving therapies. 

Our Technology

Inspired by nature, perfected by chemistry

We develop therapies that are inspired by molecules found in nature. Our proprietary synthetic chemistry capabilities allow us to begin iterating where nature left off. 

Media & News

Where elements and ingenuity meet

Cypris Therapeutics, the newest Ichor Life Sciences portfolio company, is advancing cancer treatments with groundbreaking synthetic chemistry technology. Backed by $500K in pre-seed funding, Cypris is transforming drug discovery to address brain and pancreatic cancers. Read More.

Cypris Therapeutics, Inc. took home the top prize at FSU’s Discovery Challenge for its groundbreaking treatment targeting glioblastoma, a deadly brain tumor affecting over 200,000 people annually. The therapy shows 60% greater effectiveness than current options with minimal toxicity, offering hope for patients and expanding to pancreatic and colon cancers. Read More.

Leadership

Diverse minds, singular mission

Kyle Parella, PhD

Chief Executive Officer

Jim Frederich, PhD

Chief Science Officer

Contact Us